コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 sociated immune suppression in patients with severe infection.
2 icipants fulfilled prespecified criteria for severe infection.
3 ism risk evaluation similar to any acute and severe infection.
4 drome involving complications as a result of severe infection.
5 ssociated with protection against common and severe infection.
6 LRP3-induced necrosis in the pathogenesis of severe infection.
7 wn about the mechanisms of susceptibility to severe infection.
8 fficient to provide benefit in management of severe infection.
9 compromised neutrophil recruitment, and more-severe infection.
10 g possible immuno-pathogenetic mechanisms of severe infection.
11 ated with greater T cell exhaustion and more severe infection.
12 s is characterized by a systemic response to severe infection.
13 in either group experienced a severe or very severe infection.
14 Coccidioidomycosis ranges from a mild to a severe infection.
15 thrombosis, and the major cause of death was severe infection.
16 rrelated with likelihood of acquiring a more severe infection.
17 V+ T cells might represent a novel marker of severe infection.
18 ce treatment for young infants with clinical severe infection.
19 -threatening inflammatory response caused by severe infection.
20 tion within the human body may contribute to severe infection.
21 o animal studies on the role of platelets in severe infection.
22 and 0.54 (95% CI, 0.33-0.88; P = 0.013) for severe infection.
23 mediated antiviral pathways and apoptosis in severe infection.
24 mmunity health worker with signs of clinical severe infection.
25 cules in the blood of patients with mild and severe infection.
26 nd their release into circulation induced by severe infection.
27 in intensive care units is sepsis caused by severe infection.
28 ngers as potential adjuvant therapies during severe infections.
29 an pathogen that can cause two categories of severe infections.
30 lize different virulence mechanisms to cause severe infections.
31 crobiota far more frequently than they cause severe infections.
32 e of solid organ tumor and opportunistic and severe infections.
33 e development and function and presents with severe infections.
34 e vital for controlling viral replication in severe infections.
35 n damage and improves animal survival during severe infections.
36 cated in contributing to the pathogenesis of severe infections.
37 ce factor for Staphylococcus aureus to cause severe infections.
38 address the high rate of relapse and risk of severe infections.
39 cal devices are increasingly associated with severe infections.
40 lung diseases, Pandoraea species can produce severe infections.
41 nonmyeloablative and was not associated with severe infections.
42 kines that contribute to the pathogenesis of severe infections.
43 s of enterovirus infection in mice, not just severe infections.
44 contaminated water can lead to outbreaks and severe infections.
45 ency that causes increased susceptibility to severe infections.
46 ty and shock in critically ill patients with severe infections.
47 rade 4 hematologic toxicity and 6 documented severe infections.
50 renal transplantation, 14 patients developed severe infections (16 bacterial, 4 viral, 1 parasitic).
51 with myocardial infarction); 51 (46.4%) had severe infections (21.8% with H1N1); electrolyte disturb
53 anding of the complex biological response to severe infection, a problem of growing magnitude in huma
54 loping in the lung after the resolution of a severe infection acquire tolerogenic properties that con
55 mmune dysfunction contributes to the risk of severe infections after allogeneic hematopoietic stem ce
58 on, relapse, death, allergy to rituximab, or severe infection) after transplantation among patients w
59 ection, graft pancreatitis, dehydration, and severe infections all decreased dramatically after the f
60 ctor, and it provides 75% protection against severe infection and 80% protection against death for bo
61 on model, HlaH35L immunization led to a less severe infection and decreased S. aureus levels at the c
62 on that represents a patient's response to a severe infection and has a very high mortality rate.
63 with a lower rate of virus clearance in the severe infection and is partially regulated by the expre
64 eas regions with poor perfusion are prone to severe infection and may require surgical debridement.
69 CTs) that can help to identify children with severe infections and children in need of antibiotic tre
70 mic and transcriptomic changes characterized severe infections and death, and indicated impaired mito
73 splayed similar characteristics and rates of severe infections and inflammatory episodes that those o
76 fferentiate strains responsible for mild vs. severe infections and preference for hosts (e.g., animal
78 trophil disorders confer a predisposition to severe infections and reveal novel mechanisms that contr
81 t goes wrong; underactivity resulting in the severe infections and tumours of immunodeficiency, overa
82 hil extracellular traps(NETs) in response to severe infection, and CitH3 may be a potential biomarker
83 Hypoparathyroidism is associated with more severe infection, and immunoglobulin abnormalities are m
84 ugh improved identification of children with severe infections, and better targeting of children in n
85 rine group and 11 in the rituximab group had severe infections, and cancer developed in 2 patients in
86 ed the incidence of all probable infections, severe infections, and hospitalization but did not inclu
87 a with a variable effect on the incidence of severe infections, antibiotic usage, and the duration of
89 ntibiotic resistance of pathogenic bacteria, severe infections are reported more frequently in medica
91 l kinase 2 (Tie2) are markedly imbalanced in severe infections associated with vascular leakage, yet
92 of natural T regulatory cells developed more severe infections, associated with elevated levels of IL
94 cus pyogenes infection, is less effective in severe infections because of its short postantibiotic ef
95 ent for young infants with signs of clinical severe infection but without signs of critical illness.
96 ent for young infants with signs of clinical severe infection but without signs of critical illness.
97 total cholesterol have been observed during severe infection, but it is not known whether the minor
98 eficient NET formation predisposes humans to severe infection, but, paradoxically, dysregulated NET f
99 l combinations with therapeutic potential in severe infections, but there remains a need to substanti
101 es, the associated endotoxin release (ER) in severe infections caused by gram-negative bacteria could
102 e control, noninferiority trials of selected severe infections caused by more susceptible pathogens.
104 re primary immunodeficiency characterized by severe infections caused by weakly virulent mycobacteria
105 mice lacking a functional OPN gene had more severe infections characterized by heavier bacterial loa
106 treptococcus pyogenes and is associated with severe infections characterized by rash, hypotension, mu
107 sm; a similar cognitive decline also follows severe infection, chemotherapy, or trauma and is current
109 rophils in the lungs and other organs during severe infection contributes to sepsis-induced organ dys
110 observed among isolates from recent cases of severe infection does not support a clonal basis for the
113 ndicate that neonates are more vulnerable to severe infections due to immaturity of their immune syst
117 m in immunocompromised hosts presenting with severe infections, especially if their history shows exp
118 ts from ND subjects, and also, subjects with severe infection even presented a decrease in lipoprotei
119 t in both groups), or decrease the number of severe infections (five in the G-CSF group vs. six in th
120 At present there is a focus on therapies for severe infections, for which effective treatment is most
121 not differ between groups, renal failure and severe infection-free survival were worse in those with
124 us) infections are among the most common and severe infections, garnering notoriety in an era of incr
126 d this effect predominantly in patients with severe infections [hazard ratio, 1.41; 95% confidence in
127 sion (hazards ratio [HR], 1.83), episodes of severe infection (HR, 2.15), and estimated GFR (HR, 0.89
129 group than in the supportive-care group had severe infections, impaired glucose tolerance, and weigh
132 Preterm infants are at significant risk of severe infection in early life and throughout childhood.
134 Staphylococcus aureus is a major cause of severe infection in humans and yet is carried without sy
137 , which have previously been associated with severe infection in immunologically naive hosts, are rar
138 a Toro virus (PTV) has been shown to produce severe infection in mice, modeling disease caused by the
139 up B streptococci (GBS) are a major cause of severe infection in newborns, pregnant females, and othe
142 or outpatient treatment of clinical signs of severe infection in young infants whose parents refused
144 retion of ExoU has been associated with more severe infections in both humans and animal models.
148 nhibitors or ribavirin, in the management of severe infections in hospitalized patients and immunocom
149 ensal bacterium of dog's mouth flora causing severe infections in humans after dog bites or scratches
151 to bind to human glycan receptors and cause severe infections in humans but have yet to adapt to and
152 Streptococcus (GAS) has been associated with severe infections in humans including necrotizing fascii
153 tentially with even greater ability to cause severe infections in humans or cause human-to-human tran
154 and the recently emerged H7N9 viruses cause severe infections in humans, often with fatal outcomes.
155 enza A viruses were responsible for numerous severe infections in humans, these viruses do not typica
159 ged bacteremia in immunocompetent humans and severe infections in immunocompromised individuals.
160 sionally infect humans, causing particularly severe infections in immunocompromised individuals.
161 ular, food-borne pathogen capable of causing severe infections in immunocompromised or pregnant indiv
164 Aspergillus and Mucorales species cause severe infections in patients after hematopoietic stem c
166 ther relevant pathogen-related biomarkers of severe infections include the involvement of specific cl
167 the possible presentation of metastatic and severe infection, including osteomyelitis, due to the hy
169 ortunistic human pathogen capable of causing severe infections, including pneumonia and sepsis, in im
170 strate that pneumococcal pneumonia and other severe infections increase expression of multiple compon
171 ed mice with experimental COPD also had more severe infection (increased viral titer and pulmonary in
172 proportion of infected children who develop severe infection, increasing the children's susceptibili
173 ition could act to increase the incidence of severe infection: increasing the proportion of infected
174 ronically infected IL-25(-/-) mice developed severe infection-induced intestinal inflammation associa
175 causative microorganism(s) in patients with severe infection is crucial to optimize antimicrobial us
177 spread use of ciprofloxacin in patients with severe infections is likely to result in alterations in
179 orms of SCID are characterized by recurrent, severe infections leading to death in infancy unless suc
182 ressive supportive care to determine whether severe infections might be avoided and hematologic outco
183 It has been previously hypothesized that severe infections might be due to reactivation of a pers
184 l antioxidant enzymes are overwhelmed during severe infections, mitochondrial dysfunction can occur a
185 t dysmotility or dysfunction (n=3), ACR with severe infection (n=1), and arterial graft aneurysm (n=1
188 nfection with West Nile virus (WNV) causes a severe infection of the central nervous system (CNS) wit
190 The virus causes tick-borne encephalitis, a severe infection of the CNS with a high risk for long-la
193 eminate beyond the nasopharynx and to elicit severe infections of the middle ears, lungs, and blood t
196 for the "sickness behavior" of patients with severe infection or cancer, as well as for the neuropsyc
197 counterparts, the elderly do not respond to severe infection or injury with an exaggerated inflammat
201 erns or due to increases in the frequency of severe infections or super-shedding events - population
204 wever, this regimen was also associated with severe infections, particularly when high doses of corti
205 e transfusions can be helpful in controlling severe infections progressing despite the use of appropr
206 GT resulted in a sustained reduction in the severe infection rate from 1.17 events per person-year t
209 es to the relatively diminished frequency of severe infections seen with seasonal H3N2 influenza viru
211 econdary to an underlying condition, such as severe infections, solid or hematologic malignancies, tr
213 titude of human diseases from pharyngitis to severe infections such as toxic shock syndrome and necro
214 at the expense of the host in conditions of severe infection, suggesting that MIF could represent a
217 a (IFNgamma), CXCL9, and CXCL10 and had more severe infection than EM patients carrying the 1805TG/TT
218 histology, in that strain SC5314 caused more severe infection than VE175 and the difference was stati
219 found that such transgenic mice display more severe infection than wild-type littermates when treated
220 robial peptide cathelicidin experienced less severe infection than wild-type mice in a well-establish
222 infections, particularly puerperal sepsis, a severe infection that occurs during or after childbirth.
223 erium Burkholderia pseudomallei, is an often severe infection that regularly involves respiratory dis
224 ngenital neutrophil deficiencies suffer from severe infections that are often fatal, underscoring the
225 ssociated (CA)-MRSA strains, which can cause severe infections that can result in necrotizing fasciit
226 Pseudomonas aeruginosa is a major cause of severe infections that lead to bacteremia and high patie
227 and reviews about cardiac complications and severe infections that result from long-term intravenous
228 roportion of infected children who developed severe infection, the population attributable fraction (
231 ated a gene therapy trial for X-CGD to treat severe infections unresponsive to conventional therapy.
232 isms or with chronic, previously treated, or severe infections usually require broader spectrum regim
234 o treat young infants with clinical signs of severe infection was as efficacious as an injectable pro
237 onella subspecies I serovars associated with severe infections, was confirmed to be located on the ch
238 innate immune responses are associated with severe infection, we measured the innate cells trafficki
239 dental splenectomy and risk of mortality and severe infections were analyzed using multivariable Cox
243 In addition, we reviewed 26 similar cases of severe infections which had previously been reported.
244 significantly in frequency between mild and severe infection, which suggests protection against seve
245 eans of risk stratification of patients with severe infections, which suggests new avenues for therap
246 atified young infants with clinical signs of severe infection whose parents did not accept referral t
254 en that replicates the signs and symptoms of severe infection with respiratory syncytial virus (RSV),
256 s periodic outbreaks in humans, resulting in severe infections with a high (60%) incidence of mortali
259 totoxic chemotherapy infrequently results in severe infections with viruses controlled by memory T ce
260 asis in young infants with clinical signs of severe infection, without signs of critical illness, and
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。